MX2011007857A - (1-fenil-2-piridin-4-il)etil esteres del acido benzoico como inhibidores de fosfodiesterasa. - Google Patents
(1-fenil-2-piridin-4-il)etil esteres del acido benzoico como inhibidores de fosfodiesterasa.Info
- Publication number
- MX2011007857A MX2011007857A MX2011007857A MX2011007857A MX2011007857A MX 2011007857 A MX2011007857 A MX 2011007857A MX 2011007857 A MX2011007857 A MX 2011007857A MX 2011007857 A MX2011007857 A MX 2011007857A MX 2011007857 A MX2011007857 A MX 2011007857A
- Authority
- MX
- Mexico
- Prior art keywords
- phenyl
- pyridin
- benzoic acid
- ethyl esters
- phosphodiesterase inhibitors
- Prior art date
Links
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 title 1
- 239000005711 Benzoic acid Substances 0.000 title 1
- 235000010233 benzoic acid Nutrition 0.000 title 1
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 title 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- MSYGAHOHLUJIKV-UHFFFAOYSA-N 3,5-dimethyl-1-(3-nitrophenyl)-1h-pyrazole-4-carboxylic acid ethyl ester Chemical compound CC1=C(C(=O)OCC)C(C)=NN1C1=CC=CC([N+]([O-])=O)=C1 MSYGAHOHLUJIKV-UHFFFAOYSA-N 0.000 abstract 2
- 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 abstract 2
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0065—Inhalators with dosage or measuring devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
- A61M16/10—Preparation of respiratory gases or vapours
- A61M16/14—Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Biophysics (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención se relaciona con inhibidores de la enzima fosfodiesterasa 4 (PDE4). Más particularmente, la invención se relaciona con los derivados de -fenil-2-piridinil alquilo alcoholes, métodos para preparar tales compuestos, composiciones que los comprenden, combinaciones y usos terapéuticos de los mismos (I) en donde n es 0 o 1; R1 y R2 pueden ser iguales o diferentes, y son seleccionados del grupo que consiste de: - alquilo C1-C6 lineal o ramificado, OR3 en donde R3 es un alquilo C1-C6 lineal o ramificado opcionalmente substituido por uno o más grupos cicloalquilo C3-C7 y - HNSO2R4 en donde R4 es alquilo C1-C4 opcionalmente substituido con uno o más átomos de halógeno o con un grupo C1-C4, en donde por lo menos uno de R1 y R2 es HNSO2R4. Las otras variables son como se definió en las reivindicaciones.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09001660A EP2216327A1 (en) | 2009-02-06 | 2009-02-06 | Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors |
| PCT/EP2010/000676 WO2010089107A1 (en) | 2009-02-06 | 2010-02-04 | Benzoic acid (1-phenyl-2-pyridin-4-yl) ethyl esters as phosphodiesterase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2011007857A true MX2011007857A (es) | 2011-08-15 |
Family
ID=40674203
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2011007857A MX2011007857A (es) | 2009-02-06 | 2010-02-04 | (1-fenil-2-piridin-4-il)etil esteres del acido benzoico como inhibidores de fosfodiesterasa. |
Country Status (33)
| Country | Link |
|---|---|
| US (5) | US8440834B2 (es) |
| EP (2) | EP2216327A1 (es) |
| JP (2) | JP5612610B2 (es) |
| KR (1) | KR101337728B1 (es) |
| CN (1) | CN102317262B (es) |
| AR (1) | AR075243A1 (es) |
| AU (1) | AU2010211274B2 (es) |
| BR (1) | BRPI1005695A8 (es) |
| CA (1) | CA2751494C (es) |
| CL (1) | CL2011001876A1 (es) |
| CO (1) | CO6400217A2 (es) |
| CY (1) | CY1113764T1 (es) |
| EA (1) | EA019113B1 (es) |
| ES (1) | ES2395528T3 (es) |
| GE (1) | GEP20135919B (es) |
| HR (1) | HRP20121004T1 (es) |
| IL (1) | IL214446A (es) |
| JO (1) | JO2761B1 (es) |
| MA (1) | MA33105B1 (es) |
| ME (1) | ME02325B (es) |
| MX (1) | MX2011007857A (es) |
| MY (1) | MY152048A (es) |
| NZ (1) | NZ594413A (es) |
| PE (1) | PE20120055A1 (es) |
| PL (1) | PL2393782T3 (es) |
| PT (1) | PT2393782E (es) |
| RS (1) | RS52605B (es) |
| SG (1) | SG173208A1 (es) |
| SI (1) | SI2393782T1 (es) |
| TN (1) | TN2011000346A1 (es) |
| TW (1) | TWI459945B (es) |
| UA (1) | UA102574C2 (es) |
| WO (1) | WO2010089107A1 (es) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2022783A1 (en) | 2007-08-08 | 2009-02-11 | CHIESI FARMACEUTICI S.p.A. | "Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors" |
| EP2216327A1 (en) | 2009-02-06 | 2010-08-11 | CHIESI FARMACEUTICI S.p.A. | Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors |
| CA2807406C (en) | 2010-08-03 | 2018-12-11 | Chiesi Farmaceutici S.P.A. | Pharmaceutical formulation comprising a phosphodiesterase inhibitor |
| MA34449B1 (fr) * | 2010-08-03 | 2013-08-01 | Chiesi Farma Spa | Formulation de poudre seche comprenant un inhibiteur de phosphodiesterase |
| PH12013502516A1 (en) * | 2011-06-06 | 2017-08-23 | Chiesi Farm Spa | Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors |
| CN103827088B (zh) * | 2011-09-26 | 2017-10-13 | 奇斯药制品公司 | 作为磷酸二酯酶抑制剂的1‑苯基‑2‑吡啶基烷基醇的衍生物 |
| BR112014009471A2 (pt) | 2011-10-21 | 2017-04-18 | Chiesi Farm Spa | compostos, combinação de um composto, composição farmacêutica, uso de um composto, dispositivo e kit |
| WO2013087749A1 (en) * | 2011-12-16 | 2013-06-20 | Chiesi Farmaceutici S.P.A. | Potentiation induced by pde4 inhibitors in the treatment of leukemia |
| IN2014DN10239A (es) | 2012-06-04 | 2015-08-07 | Chiesi Farma Spa | |
| RU2015121043A (ru) | 2012-12-05 | 2017-01-11 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | Производные фенилэтилпиридина в качестве ингибиторов PDE-4 |
| CN104822659A (zh) * | 2012-12-05 | 2015-08-05 | 奇斯药制品公司 | 作为磷酸二酯酶抑制剂的1-苯基-2-吡啶基烷基醇衍生物 |
| BR112015012949A2 (pt) | 2012-12-05 | 2017-07-11 | Chiesi Farm Spa | composto, composição farmaceutica, uso de um composto, dispositivo inalatório e kit |
| BR112015012716A2 (pt) | 2012-12-05 | 2017-07-11 | Chiesi Farm Spa | derivados de feniletilpiridina como inibidores de pde4 |
| US9427376B2 (en) | 2013-10-10 | 2016-08-30 | Chiesi Farmaceutici S.P.A. | Process for preparing pharmaceutical formulations for inhalation comprising a high-dosage strength active ingredient |
| KR102240865B1 (ko) * | 2013-10-22 | 2021-04-16 | 키에시 파르마슈티시 엣스. 피. 에이. | Pde4 억제제의 제조 방법 |
| HK1225384A1 (zh) | 2013-12-05 | 2017-09-08 | 奇斯药制品公司 | 用於治疗呼吸病的二苯甲基衍生物 |
| WO2015082616A1 (en) | 2013-12-05 | 2015-06-11 | Chiesi Farmaceutici S.P.A. | Heteroaryl derivatives for the treatment of respiratory diseases |
| WO2015185128A1 (en) * | 2014-06-04 | 2015-12-10 | Chiesi Farmaceutici S.P.A. | 3,5-dichloro,4-(3,4-(cyclo-)alkoxyphenyl)- 2-carbonyloxy)ethyl)pyridine derivatives as pde-4 inhibitors |
| WO2015185130A1 (en) * | 2014-06-04 | 2015-12-10 | Chiesi Farmaceutici S.P.A. | 3,5-dichloro,4-(3,4-(cyclo-)alkoxyphenyl)--2-carbonyloxy)ethyl)pyridine derivatives as pde-4 inhibitors |
| US9763924B2 (en) | 2014-06-05 | 2017-09-19 | Chiesi Farmaceutici S.P.A. | Aminoester derivatives |
| US9326976B2 (en) | 2014-06-05 | 2016-05-03 | Chiesi Farmaceutici S.P.A. | Carbamate derivatives |
| WO2017089347A1 (en) | 2015-11-25 | 2017-06-01 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas |
| EP3487501A1 (en) * | 2016-07-20 | 2019-05-29 | Allergan, Inc. | Methods, compositions, and compounds for treatment of dermatological and ocular conditions |
| EP3732164A1 (en) | 2017-12-28 | 2020-11-04 | Chiesi Farmaceutici S.p.A. | Use of 1-phenyl-2-pyridinyl alkyl alcohol derivatives for treating cystic fibrosis |
| KR102784384B1 (ko) | 2018-07-27 | 2025-03-21 | 키에시 파르마슈티시 엣스. 피. 에이. | 흡입용 건조 분말 제제를 위한 신규 담체 입자 |
| CN115466169B (zh) * | 2021-06-10 | 2024-03-26 | 中国医学科学院药物研究所 | 取代邻苯二酚醚类化合物及其制备方法和应用 |
| WO2023117985A1 (en) | 2021-12-21 | 2023-06-29 | Chiesi Farmaceutici S.P.A. | Dry powder formulations filled in an inhaler with improved resistance to humidity |
| WO2023208982A1 (en) | 2022-04-27 | 2023-11-02 | Chiesi Farmaceutici S.P.A. | Crystal form of a pde4 inhibitor |
| WO2024027901A1 (en) | 2022-08-02 | 2024-02-08 | Chiesi Farmaceutici S.P.A. | Predictive biomarker of clinical response to a pde4 inhibitor |
| CA3267958A1 (en) | 2022-09-22 | 2024-03-28 | Chiesi Farmaceutici S.P.A. | CAPSULE INHALATOR FOR THE ADMINISTRATION OF A PHOSPHODIESTERASE-4 INHIBITOR |
| CA3268102A1 (en) | 2022-09-22 | 2024-03-28 | Chiesi Farmaceutici S.P.A. | CAPSULE INHALATOR FOR THE ADMINISTRATION OF A PHOSPHODIESTERASE-4 INHIBITOR |
| JP2025532672A (ja) | 2022-09-22 | 2025-10-01 | キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ | ホスホジエステラーゼ－４阻害剤の投与のためのカプセル吸入器 |
| GB202306663D0 (en) | 2023-05-05 | 2023-06-21 | Union Therapeutics As | Combination therapy |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW263495B (es) * | 1992-12-23 | 1995-11-21 | Celltech Ltd | |
| GB9304919D0 (en) * | 1993-03-10 | 1993-04-28 | Celltech Ltd | Chemical compounds |
| RU2137754C1 (ru) * | 1993-07-02 | 1999-09-20 | Бик Гульден Ломберг Хемише Фабрик ГмбХ | Фторалкоксизамещенные бензамиды, способ их получения и фармацевтическая композиция на их основе |
| GB9412573D0 (en) * | 1994-06-22 | 1994-08-10 | Celltech Ltd | Chemical compounds |
| WO2008006509A1 (en) | 2006-07-14 | 2008-01-17 | Chiesi Farmaceutici S.P.A. | Derivatives of 1-phenyl-2-pyridynyl alkylene alcohols as phosphodiesterase inhibitors |
| EP2022783A1 (en) | 2007-08-08 | 2009-02-11 | CHIESI FARMACEUTICI S.p.A. | "Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors" |
| EP2070913A1 (en) | 2007-12-14 | 2009-06-17 | CHIESI FARMACEUTICI S.p.A. | Ester derivatives as phosphodiesterase inhibitors |
| EP2110375A1 (en) | 2008-04-14 | 2009-10-21 | CHIESI FARMACEUTICI S.p.A. | Phosphodiesterase-4 inhibitors belonging to the tertiary amine class |
| EP2216327A1 (en) | 2009-02-06 | 2010-08-11 | CHIESI FARMACEUTICI S.p.A. | Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors |
| CA2807406C (en) | 2010-08-03 | 2018-12-11 | Chiesi Farmaceutici S.P.A. | Pharmaceutical formulation comprising a phosphodiesterase inhibitor |
| MA34449B1 (fr) | 2010-08-03 | 2013-08-01 | Chiesi Farma Spa | Formulation de poudre seche comprenant un inhibiteur de phosphodiesterase |
| PH12013502516A1 (en) | 2011-06-06 | 2017-08-23 | Chiesi Farm Spa | Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors |
| CN103827088B (zh) | 2011-09-26 | 2017-10-13 | 奇斯药制品公司 | 作为磷酸二酯酶抑制剂的1‑苯基‑2‑吡啶基烷基醇的衍生物 |
| BR112014009471A2 (pt) | 2011-10-21 | 2017-04-18 | Chiesi Farm Spa | compostos, combinação de um composto, composição farmacêutica, uso de um composto, dispositivo e kit |
| IN2014DN10239A (es) | 2012-06-04 | 2015-08-07 | Chiesi Farma Spa | |
| CN104822659A (zh) | 2012-12-05 | 2015-08-05 | 奇斯药制品公司 | 作为磷酸二酯酶抑制剂的1-苯基-2-吡啶基烷基醇衍生物 |
-
2009
- 2009-02-06 EP EP09001660A patent/EP2216327A1/en not_active Withdrawn
-
2010
- 2010-02-03 JO JO201033A patent/JO2761B1/en active
- 2010-02-04 PE PE2011001441A patent/PE20120055A1/es active IP Right Grant
- 2010-02-04 EP EP10704746A patent/EP2393782B1/en active Active
- 2010-02-04 RS RS20120547A patent/RS52605B/sr unknown
- 2010-02-04 TW TW099103291A patent/TWI459945B/zh active
- 2010-02-04 AR ARP100100311A patent/AR075243A1/es not_active Application Discontinuation
- 2010-02-04 AU AU2010211274A patent/AU2010211274B2/en active Active
- 2010-02-04 MX MX2011007857A patent/MX2011007857A/es active IP Right Grant
- 2010-02-04 MA MA34150A patent/MA33105B1/fr unknown
- 2010-02-04 SI SI201030094T patent/SI2393782T1/sl unknown
- 2010-02-04 BR BRPI1005695A patent/BRPI1005695A8/pt not_active Application Discontinuation
- 2010-02-04 KR KR1020117016842A patent/KR101337728B1/ko active Active
- 2010-02-04 JP JP2011548600A patent/JP5612610B2/ja active Active
- 2010-02-04 WO PCT/EP2010/000676 patent/WO2010089107A1/en not_active Ceased
- 2010-02-04 NZ NZ594413A patent/NZ594413A/xx unknown
- 2010-02-04 ME MEP-2016-19A patent/ME02325B/me unknown
- 2010-02-04 PT PT107047466T patent/PT2393782E/pt unknown
- 2010-02-04 SG SG2011056165A patent/SG173208A1/en unknown
- 2010-02-04 GE GEAP201012324A patent/GEP20135919B/en unknown
- 2010-02-04 ES ES10704746T patent/ES2395528T3/es active Active
- 2010-02-04 EA EA201190099A patent/EA019113B1/ru unknown
- 2010-02-04 CN CN201080006643.7A patent/CN102317262B/zh active Active
- 2010-02-04 MY MYPI2011003639 patent/MY152048A/en unknown
- 2010-02-04 PL PL10704746T patent/PL2393782T3/pl unknown
- 2010-02-04 CA CA2751494A patent/CA2751494C/en active Active
- 2010-02-04 HR HRP20121004AT patent/HRP20121004T1/hr unknown
- 2010-02-04 UA UAA201108827A patent/UA102574C2/ru unknown
- 2010-02-05 US US12/700,926 patent/US8440834B2/en active Active
-
2011
- 2011-07-13 TN TN2011000346A patent/TN2011000346A1/fr unknown
- 2011-08-04 IL IL214446A patent/IL214446A/en active IP Right Grant
- 2011-08-04 CL CL2011001876A patent/CL2011001876A1/es unknown
- 2011-08-04 CO CO11098671A patent/CO6400217A2/es not_active Application Discontinuation
-
2012
- 2012-09-14 US US13/618,346 patent/US20130012487A1/en not_active Abandoned
- 2012-12-04 CY CY20121101183T patent/CY1113764T1/el unknown
-
2013
- 2013-06-28 US US13/930,304 patent/US8648204B2/en active Active
- 2013-12-17 US US14/108,731 patent/US8859778B2/en active Active
-
2014
- 2014-09-04 JP JP2014179895A patent/JP2015038079A/ja active Pending
- 2014-09-10 US US14/482,287 patent/US9056176B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2011000346A1 (en) | Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors | |
| MX361618B (es) | Formulaciones farmacéuticas que comprenden derivados de nitrocatecol y métodos para hacer las mismas. | |
| SG195319A1 (en) | Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors | |
| PH12016500216A1 (en) | Stable pharmaceutical composition and methods of using same | |
| JO3181B1 (ar) | مشتقات كمحول ثاني الكيل البايردينيل - أحادي الفينيل كأنزيم ثنائي استرات الفوسفود | |
| WO2008030744A3 (en) | Inhibitors of c-met and uses thereof | |
| UA95796C2 (ru) | Производные n-циклопропил-бензиламида, способ их получения, фунгицидная композиция и способ борьбы с фитопатогенными грибами | |
| MX2010010135A (es) | Derivados de hidroximoil-tetrazol fungicidas. | |
| NZ596228A (en) | Compositions and methods for the treatment of inflammation | |
| UY32631A (es) | Derivados de ciclopenta[c]pirrol-2-carboxilatos, su preparación y su aplicación en terapéutica. | |
| MY140841A (en) | Indozolone derivatives as 11b-hsd1 inhibitors | |
| UY32630A (es) | Derivados de 7-aza-espiro[3.5]nonano-7-carboxilatos, su preparación y su aplicación en terapéutica. | |
| UA97821C2 (en) | Cyclized derivatives as eg-5 inhibitors | |
| WO2013057013A3 (en) | Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors | |
| AU2009310099A8 (en) | Agricultural compositions | |
| IN2014DN07483A (es) | ||
| MX2010006787A (es) | Análogos halogenados de agentes anti-fibroticos. | |
| NZ592429A (en) | PHENANTHROINDOLIZIDINE DERIVATIVE AND NFkB INHIBITOR CONTAINING SAME AS ACTIVE INGREDIENT | |
| UY32632A (es) | Derivados de ciclopenta[c]pirrolilalquilcarbamatos de heterociclos de 5 miembros, su preparación y su aplicación en terapéutica. | |
| MY147188A (en) | Substituted imidazole compounds as ksp inhibitors | |
| BR112014013906A2 (pt) | ésteres de fosfato aromáticos como componentes de formulação agroquímica | |
| MX339361B (es) | Derivados de alternano. | |
| WO2009140101A3 (en) | Imidazopyridine compounds useful as mmp-13 inhibitors | |
| IN2014DN06122A (es) | ||
| MX339727B (es) | Composicion farmaceutica que comprende un compuesto de 11-desoxi-prostaglandina y metodo para estabilizar el compuesto. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |